Journal Article Summary
The article investigates the use of low-dose dextromethorphan (DXM) as a potential treatment for fibromyalgia (FM), a chronic pain condition that currently has limited effective treatment options. FM is characterized by widespread pain and various associated symptoms, making it a challenging condition for patients and healthcare providers alike. The study is significant as it explores a novel approach to managing FM symptoms, particularly given the limited success of existing medications and the need for new therapeutic options.
In this pilot trial, 14 women diagnosed with FM participated in a single-blind, placebo-controlled study. Participants first received a placebo for five weeks, followed by a ten-week treatment period with 20 mg of DXM daily. While the study did not find significant differences in overall pain or physical activity between the placebo and DXM phases, exploratory analyses indicated that pain levels were significantly lower during the DXM treatment compared to the placebo, suggesting some potential benefit from the medication.
However, the study has several limitations, including a small sample size that restricts the generalizability of the findings and the absence of objective pain assessments. Additionally, the single-blind design may introduce bias, and the short duration of treatment raises questions about the long-term effectiveness of DXM. Patients considering this treatment should discuss it with their healthcare professionals, especially given the need for more research before DXM can be recommended as a viable option for managing FM.
Medication Safety Note
This journal article summary is provided for educational purposes only and is not medical advice. Always consult a licensed healthcare professional before starting, stopping, or changing any medication.
Article Cited
- Mueller Christina, Ness Timothy J, Younger Jarred W. Low-Dose Dextromethorphan for the Treatment of Fibromyalgia Pain: Results from a Longitudinal, Single-Blind, Placebo-Controlled Pilot Trial. Journal of Pain Research 2021. DOI: 10.2147/JPR.S285609. PMID: 33542651. PMCID: PMC7851375.
Featured Pill Pals Product
Tizanidine 2 mg Capsules --- Generic For Zanaflex --- Ascend
Tizanidine 2 mg Capsules — Generic For Zanaflex — Ascend is available through Pill Pals Pharmacy with cash-pay pharmacy pricing and free shipping where available. Prescription required.
Request a prescription transfer and our pharmacy team will help coordinate the next step.
